glp-1 drugs and breast cancer The Impact Safety of GLP‐1 Agents and Ozempic & Co.: Better Survival

Discontinuation might be a factor limiting neuroprotective benefits of GLP1 receptor agonists

Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target mendelian randomization and clinical trials

Final Thoughts Medications that contain GLP-1 have changed the way people lose weight and control their diabetes, especially women over 50 who need help lowering their blood sugar

Pharmaceutical companies must enhance their efforts to ensure a stable supply of GLP-1 receptor agonists globally, while governments and healthcare systems should issue guidelines to guarantee the consistent availability of GLP-1 receptor agonists for patients